189 related articles for article (PubMed ID: 1521037)
41. Biochemical and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse.
Abe K; Taguchi K; Wasai T; Ren J; Utsunomiya I; Shinohara T; Miyatake T; Sano T
Brain Res; 2001 Jul; 907(1-2):134-8. PubMed ID: 11430895
[TBL] [Abstract][Full Text] [Related]
42. Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Schlüter OM; Fornai F; Alessandrí MG; Takamori S; Geppert M; Jahn R; Südhof TC
Neuroscience; 2003; 118(4):985-1002. PubMed ID: 12732244
[TBL] [Abstract][Full Text] [Related]
43. Immunohistochemical evaluation of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopaminergic nigrostriatal neurons of young adult mice using dopamine and tyrosine hydroxylase antibodies.
Mori S; Fujitake J; Kuno S; Sano Y
Neurosci Lett; 1988 Jul; 90(1-2):57-62. PubMed ID: 2901058
[TBL] [Abstract][Full Text] [Related]
44. Biochemical evaluation of the neurotoxicity of MPTP and MPP⁺ in embryonic and newborn mice.
Sai T; Uchida K; Nakayama H
J Toxicol Sci; 2013; 38(3):445-58. PubMed ID: 23665943
[TBL] [Abstract][Full Text] [Related]
45. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase, MPTP metabolism and neurotoxicity.
Heikkila RE; Hess A; Duvoisin RC
Life Sci; 1985 Jan; 36(3):231-6. PubMed ID: 3917525
[TBL] [Abstract][Full Text] [Related]
46. Cholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson's Disease.
Hilario WF; Herlinger AL; Areal LB; de Moraes LS; Ferreira TA; Andrade TE; Martins-Silva C; Pires RG
J Mol Neurosci; 2016 Dec; 60(4):453-464. PubMed ID: 27660217
[TBL] [Abstract][Full Text] [Related]
47. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
[TBL] [Abstract][Full Text] [Related]
48. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
Saporito MS; Brown EM; Miller MS; Carswell S
J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
[TBL] [Abstract][Full Text] [Related]
49. Involvement of cytochrome P450 2E1 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse model of Parkinson's disease.
Vaglini F; Pardini C; Viaggi C; Bartoli C; Dinucci D; Corsini GU
J Neurochem; 2004 Oct; 91(2):285-98. PubMed ID: 15447662
[TBL] [Abstract][Full Text] [Related]
50. [Recovery of nigrostriatal and mesolimbic dopaminergic system following administration of ganglioside in MPTP-treated mice].
Date I; Asari S; Nishimoto A; Felten DL
No To Shinkei; 1990 Nov; 42(11):1035-40. PubMed ID: 2076347
[TBL] [Abstract][Full Text] [Related]
51. Nicotine, but not cotinine, partially protects dopaminergic neurons against MPTP-induced degeneration in mice.
Parain K; Marchand V; Dumery B; Hirsch E
Brain Res; 2001 Feb; 890(2):347-50. PubMed ID: 11164803
[TBL] [Abstract][Full Text] [Related]
52. Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.
Shimoji M; Zhang L; Mandir AS; Dawson VL; Dawson TM
Brain Res Mol Brain Res; 2005 Mar; 134(1):103-8. PubMed ID: 15790534
[TBL] [Abstract][Full Text] [Related]
53. Prolonged alterations in canine striatal dopamine metabolism following subtoxic doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 4'-amino-MPTP are linked to the persistence of pyridinium metabolites.
Johannessen JN; Sobotka TJ; Weise VK; Markey SP
J Neurochem; 1991 Sep; 57(3):981-90. PubMed ID: 1677682
[TBL] [Abstract][Full Text] [Related]
54. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
[TBL] [Abstract][Full Text] [Related]
55. Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo.
Ferger B; Spratt C; Earl CD; Teismann P; Oertel WH; Kuschinsky K
Naunyn Schmiedebergs Arch Pharmacol; 1998 Sep; 358(3):351-9. PubMed ID: 9774223
[TBL] [Abstract][Full Text] [Related]
56. Differential interactive effects of gliotoxin and MPTP in the substantia nigra and the locus coeruleus in BALB/c mice.
Chang FW; Wang SD; Lu KT; Lee EH
Brain Res Bull; 1993; 31(3-4):253-66. PubMed ID: 7683960
[TBL] [Abstract][Full Text] [Related]
57. Systemic administration of proteasome inhibitor protects against MPTP neurotoxicity in mice.
Oshikawa T; Kuroiwa H; Yano R; Yokoyama H; Kadoguchi N; Kato H; Araki T
Cell Mol Neurobiol; 2009 Jul; 29(5):769-77. PubMed ID: 19370411
[TBL] [Abstract][Full Text] [Related]
58. Recovery of hypothalamic tuberoinfundibular dopamine neurons from acute toxicant exposure is dependent upon protein synthesis and associated with an increase in parkin and ubiquitin carboxy-terminal hydrolase-L1 expression.
Benskey M; Behrouz B; Sunryd J; Pappas SS; Baek SH; Huebner M; Lookingland KJ; Goudreau JL
Neurotoxicology; 2012 Jun; 33(3):321-31. PubMed ID: 22342763
[TBL] [Abstract][Full Text] [Related]
59. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease.
Pifl C; Schingnitz G; Hornykiewicz O
Neurosci Lett; 1988 Oct; 92(2):228-33. PubMed ID: 3263594
[TBL] [Abstract][Full Text] [Related]
60. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on retinal dopaminergic system in mice.
Hamilton WR; Trickler WJ; Robinson BL; Paule MG; Ali SF
Neurosci Lett; 2012 May; 515(2):107-10. PubMed ID: 22414866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
